These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20614563)

  • 1. Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors.
    Hutchinson L
    Nat Rev Clin Oncol; 2010 Jul; 7(7):358. PubMed ID: 20614563
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
    Scaltriti M; Chandarlapaty S; Prudkin L; Aura C; Jimenez J; Angelini PD; Sánchez G; Guzman M; Parra JL; Ellis C; Gagnon R; Koehler M; Gomez H; Geyer C; Cameron D; Arribas J; Rosen N; Baselga J
    Clin Cancer Res; 2010 May; 16(9):2688-95. PubMed ID: 20406840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
    Scaltriti M; Nuciforo P; Bradbury I; Sperinde J; Agbor-Tarh D; Campbell C; Chenna A; Winslow J; Serra V; Parra JL; Prudkin L; Jimenez J; Aura C; Harbeck N; Pusztai L; Ellis C; Eidtmann H; Arribas J; Cortes J; de Azambuja E; Piccart M; Baselga J
    Clin Cancer Res; 2015 Feb; 21(3):569-76. PubMed ID: 25467182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.
    de Mello RA; de Vasconcelos A; Ribeiro RA; Pousa I; Afonso N; Pereira D; Rodrigues H
    Recent Pat DNA Gene Seq; 2012 Apr; 6(1):56-63. PubMed ID: 22239685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
    Growdon WB; Groeneweg J; Byron V; DiGloria C; Borger DR; Tambouret R; Foster R; Chenna A; Sperinde J; Winslow J; Rueda BR
    Gynecol Oncol; 2015 Apr; 137(1):160-6. PubMed ID: 25602714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
    Castañeda CA; Gomez HL
    Nat Rev Clin Oncol; 2009 Jun; 6(6):308-9. PubMed ID: 19483734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
    Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.
    Gorbatenko A; Søkilde R; Sorensen EE; Newie I; Persson H; Morancho B; Arribas J; Litman T; Rovira C; Pedersen SF
    Sci Rep; 2019 Mar; 9(1):3352. PubMed ID: 30833639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes.
    Gorbatenko A; Olesen CW; Loebl N; Sigurdsson HH; Bianchi C; Pedraz-Cuesta E; Christiansen J; Pedersen SF
    Biochem J; 2016 Nov; 473(21):4027-4044. PubMed ID: 27609814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
    Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
    Stravodimou A; Voutsadakis IA
    Anticancer Res; 2019 Jul; 39(7):3295-3301. PubMed ID: 31262849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular predictors of response to trastuzumab and lapatinib in breast cancer.
    Esteva FJ; Yu D; Hung MC; Hortobagyi GN
    Nat Rev Clin Oncol; 2010 Feb; 7(2):98-107. PubMed ID: 20027191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.